NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?

Anti-PD1 and anti-PDL1 immunotherapy has transformed urothelial carcinoma treatment. Pembrolizumab is the only immunotherapy agent shown to have survival benefit compared with standard chemotherapy after progression on platinum-containing chemotherapy. Initial National Institute for Health and Care...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Shilpa, Kamat, Ashish M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338128/
https://www.ncbi.nlm.nih.gov/pubmed/32632305
http://dx.doi.org/10.1038/s41585-020-0357-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338128/
https://www.ncbi.nlm.nih.gov/pubmed/32632305
http://dx.doi.org/10.1038/s41585-020-0357-1

Ejemplares similares